Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets childhood sarcomas that returned

NCT ID NCT07222735

Recruiting now Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment for children and young adults up to age 21 with sarcomas that have come back or not responded to standard therapy. The treatment combines a special type of immune cell (B7-H3-CAR T cells) with targeted radiation and chemotherapy to see if it is safe and can shrink tumors. About 42 participants will be enrolled at St. Jude Children's Research Hospital.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma osteosarcoma pediatric osteosarcoma rhabdomyosarcoma sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILDHOOD OSTEOSARCOMA CHILDHOOD RHABDOMYOSARCOMA CHILDHOOD SOFT TISSUE SARCOMA EWING SARCOMA SARCOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.